Abstract
Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.
Keywords: Intracerebral haemorrhage, hypertension, imidazoline receptors, inflammation, excitotoxicity, apoptosis.
Current Molecular Medicine
Title:Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Volume: 18 Issue: 4
Author(s): J. Mahmoudi, A. Majdi, S. Lattanzi, M. Di Napoli, E.M. Bershad, C.M.P. Rodrigues and A.A. Divani*
Affiliation:
- Department of Neurology, University of Minnesota, Minneapolis, MN,United States
Keywords: Intracerebral haemorrhage, hypertension, imidazoline receptors, inflammation, excitotoxicity, apoptosis.
Abstract: Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.
Export Options
About this article
Cite this article as:
Mahmoudi J. , Majdi A. , Lattanzi S. , Di Napoli M. , Bershad E.M. , Rodrigues C.M.P. and Divani A.A.*, Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666180926163712
DOI https://dx.doi.org/10.2174/1566524018666180926163712 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum
Disorders
Current Pharmaceutical Design Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Therapeutic Moderate Hypothermia and Fever
Current Pharmaceutical Design Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions
Drug Design Reviews - Online (Discontinued) Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Hypothyroidism and High Plasma and Urine Iodine Levels Related to the Use of Gastrografin
Current Pediatric Reviews Critical Issues in Delivery of RNAi Therapeutics In Vivo
Current Pharmaceutical Biotechnology Mitochondria-Targeted Drugs
Current Molecular Pharmacology Review: Metabolism of Immunosuppressant Drugs
Current Drug Metabolism Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry